Biocon Biologics approves Rs 1,125 crore investment from Goldman Sachs Ruchika Sharma9 Nov 2020 1:00 PM ISTAs per the terms of the proposed agreement, Goldman Sachs will be issued Optionally Convertable Debentures at a post money equity valuation of USD...
Biocon arm, Mylan launch diabetes drug Semglee in US Medical Dialogues Bureau1 Sept 2020 10:45 AM IST"The commercialization of our insulin glargine in the US represents another milestone achievement for Biocon in making insulin-based therapy...
Tata Capital Growth Fund to invest Rs 225 crore in Biocon Biologics Ruchika Sharma1 Aug 2020 11:42 AM ISTPost the completion of this transaction, Biocon will hold 95.25 per cent stake in Biocon Biologics, the biotechnology major added.
Biocon Biologics, Voluntis collaborate for digital therapeutics for diabetics patients Ruchika Sharma22 July 2020 1:22 PM ISTNew Delhi: Biocon Biologics on Tuesday announced a global collaboration agreement with Voluntis to develop and distribute digital therapeutics...
Biocon to invest over Rs 1493 crore capex for current fiscal Ruchika Sharma4 July 2020 1:40 PM ISTThe capex will be funded through a combination of contribution from internal accruals, debt raise as well as an additional private equity investment...
Biocon Biologics gets DCGI nod for use of CytoSorb in critical COVID-19 cases Hina Zahid28 May 2020 2:13 PM ISTBiopharmaceutical company Biocon on Wednesday announced that its subsidiary Biocon Biologics has received the Drugs Controller General of India's...
Biocon Biologics gets EU GMP Certification for Bengaluru Manufacturing Facilities Ruchika Sharma21 May 2020 1:06 PM ISTBengaluru: Biocon Ltd has announced that its subsidiary Biocon Biologics India Ltd. has received the Certificate of GMP compliance from EMA for...
Biocon Biologics gets EU GMP Certification for Drug Substance Facilities, Bengaluru Ruchika Sharma13 May 2020 11:44 AM ISTBengaluru: Biocon Biologics India Ltd., a subsidiary of Biocon Ltd. has received the Certificate of GMP compliance from EMA represented by the...
